665 related articles for article (PubMed ID: 28454119)
1. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
3. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
4. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
[TBL] [Abstract][Full Text] [Related]
6. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
8. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
Owonikoko TK; Zhang G; Lallani SB; Chen Z; Martinson DE; Khuri FR; Lonial S; Marcus A; Sun SY
PLoS One; 2019; 14(2):e0206309. PubMed ID: 30807575
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
12. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
13. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
14. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
Krug S; Mordhorst JP; Moser F; Theuerkorn K; Ruffert C; Egidi M; Rinke A; Gress TM; Michl P
PLoS One; 2019; 14(6):e0218953. PubMed ID: 31237925
[TBL] [Abstract][Full Text] [Related]
15. Target therapies plus somatostatin analogs in NETs: a network meta-analysis.
Pusceddu S; Facciorusso A; Giacomelli L; Prinzi N; Corti F; Niger M; Milione M; Coppa J; Cascella T; Pulice I; Biamonte L; Papa S; Di Bartolomeo M; Shah A; Sacco R; de Braud F
Endocr Relat Cancer; 2021 Jun; 28(7):467-479. PubMed ID: 33979777
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
17. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
18. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
19. VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.
Villaume K; Blanc M; Gouysse G; Walter T; Couderc C; Nejjari M; Vercherat C; Cordier-Bussat M; Roche C; Scoazec JY
Neuroendocrinology; 2010; 91(3):268-78. PubMed ID: 20389030
[TBL] [Abstract][Full Text] [Related]
20. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
